Skip to main content
TipRanks
Go Ultimate75% OFF

Illumina (1ILMN) Q3 2026 Earnings Report

2 Followers

IT:1ILMN Q3 2026 EPS Results

Actual EPS
EUR 1.31
Consensus EPS
EUR 1.23
Beat/Miss
Beat by +EUR 0.08
One Year Ago EPS
EUR 1.22

IT:1ILMN Q3 2026 Revenue Results

Actual Revenue
EUR 1.03B
Expected Revenue
EUR 1.05B
Beat/Miss
Missed by -EUR 20.91M
YoY Revenue Growth
+4.34%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/29/2026
Time
After Close
Conference Call
Thursday, October 29, 2026
IT:1ILMN Upcoming Earnings

Illumina's next earnings date is estimated for February 11, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

IT:1ILMN Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 29, 2026|% Change Since:-27.36%|
Earnings Call Sentiment|Positive

The call was strongly positive. Illumina reported revenue, margin, EPS, cash flow, clinical demand, and NovaSeq X placements above expectations, raised full-year guidance, and highlighted expanding opportunities in clinical sequencing, multi-omics, software, and AI-based data sets. The main challenges were declines in research and applied markets, weaker instrument revenue in certain regions, ongoing pricing and cost headwinds, slower clinical conversion to the NovaSeq X, and uncertainty related to China and trade restrictions.

Company Guidance

Illumina raised fiscal-year 2026 revenue guidance by $30 million at the midpoint to $4.64 to 4.66 billion, expects rest of world organic growth greater than 5%, rest of world organic sequencing consumable growth of mid-single digits, low double-digit instrument growth, operating margins of approximately 23.6% at the high end of our previous guidance, and diluted EPS guidance of $5.40 to $5.45, representing year-over-year growth of 12% to 13%; for the fourth quarter, it expects revenue of $1.22 to 1.24 billion, rest of the world organic growth of approximately 4.5%, EPS of $1.51 to $1.56, operating margin of approximately 25%, and 5% to 6% growth in consumables overall. For 2026, it continues to expect mid-teens clinical growth and mid to high single-digit declines in research and applied sequencing consumables for rest of world, while clinical growth is expected to remain in the mid-teens; it also expects operating margins of approximately 25% in the second half of 2026, up about 400 basis points versus 2024. For 2027, management said it will provide full guidance on the fourth quarter earnings call, described high single digit in that range as the current consumables framework, and said new products and BioInsight could add one to two points of growth for 2027.

  • Q3 Revenue and Earnings Exceeded GuidanceRest-of-world organic revenue grew 5%, operating margin was 25%, which was 100 basis points above guidance, and diluted EPS was $1.44, up 7% year-over-year and above the high end of the guidance range.
  • Full-Year Guidance RaisedFull-year revenue guidance was raised by $30 million at the midpoint to $4.64 billion to $4.66 billion. Operating margin is now expected to be approximately 23.6%, and diluted EPS guidance increased by $0.08 at the midpoint to $5.40 to $5.45, representing year-over-year growth of 12% to 13%.
  • Strong Clinical Consumables GrowthClinical sequencing consumables grew 14% in rest-of-world markets in Q3, and management continued to expect mid-teens clinical consumables growth for 2026. Management said clinical demand remained strong, with a rich pipeline of new tests and clinical trials.
  • NovaSeq X Placements Remained ElevatedIllumina placed over 80 NovaSeq X instruments in Q3, bringing placements to approximately 360 over the last four quarters, more than in the first year of launch. Management said demand was being driven by broader adoption of sequencing-based diagnostics and more sequencing-intensive assays.
  • Expanding NovaSeq X Installed Base Supports ConsumablesApproximately 84% of high-throughput volume and 60% of revenue was on the NovaSeq X. Management said the growing installed base would support additional consumables revenue for years to come, and elevated placements were expected to remain a growth driver.
  • Strong Sequencing ActivityGigabase output growth on connected high- and mid-throughput instruments remained above 30%, which management said showed that demand remained strong.
  • Sequencing Consumables Revenue IncreasedSequencing consumables revenue was $792 million, up 6% year-over-year and up 5% on an organic rest-of-world basis. High-throughput volume drove most of the growth as the NovaSeq X installed base expanded and clinical customers brought instruments online.
  • Sequencing Services and Microarrays GrewSequencing service and other revenue was $158 million, up 8% on a rest-of-world organic basis, while microarrays and other revenue was $110 million, up 2% on a rest-of-world organic basis. Microarrays and other revenue included SomaLogic revenue that outperformed the initial deal model.
  • Margin Expansion and Disciplined ExecutionGross margin was 69.4%, up 20 basis points year-over-year. Management expects operating margins of approximately 25% in the second half of 2026, up about 400 basis points versus 2024, despite stated headwinds from electronic component pricing, shipping costs, and tariffs.
  • Strong Cash Flow and Balance SheetCash flow from operations was $419 million and free cash flow was $378 million in Q3. The company ended the quarter with approximately $1.34 billion in cash equivalents and short-term investments, $1.79 billion in total debt, and a leverage ratio of approximately 1.4 times gross debt to last-twelve-month EBITDA.
  • Share Repurchases ContinuedIllumina repurchased $9 million of stock during the quarter and had approximately $1.8 billion remaining under its current share repurchase authorizations. Management said it intended to continue repurchasing shares opportunistically.
  • Billion Cell Atlas Progress and Customer InterestThe Billion Cell Atlas was more than halfway complete and was advancing toward an AI-ready perturbation data set. GSK joined the consortium, and management reported growing interest from other companies seeking access to the completed Atlas. The program was also converting more backlog to revenue.
  • BioInsight and AI Innovation ExpandedIllumina launched the BioInsight platform, combining analysis applications, AI models, and curated biological data. Its SpliceAI2 model identified 17% more disease-relevant splice variants than other splicing models in rare-disease research data sets.
  • Multi-Omics Portfolio Positioned for GrowthManagement highlighted the integration of genomics, transcriptomics, methylation, and proteomics across bulk, single-cell, and spatial approaches. The company said its multi-omics portfolio and SomaLogic acquisition positioned it to benefit as research activity returns, with new products and data expected to begin contributing to results in 2026 and particularly in 2027 and beyond.
  • China Returned to GrowthManagement said Illumina was pleased to be back to growth in China and remained committed to supporting Chinese customers, driving innovation, and working with regulators to establish a path forward in the market.

IT:1ILMN Earnings History

IT:1ILMN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 11, 20272026 (Q4)1.39-1.22――
Oct 29, 20262026 (Q3)1.231.311.227.46% (+0.09)
Jul 30, 20262026 (Q2)1.111.191.0810.08% (+0.11)
Apr 30, 20262026 (Q1)0.961.040.8818.56% (+0.16)
Feb 05, 20262025 (Q4)1.131.220.8642.11% (+0.36)
Oct 30, 20252025 (Q3)1.061.221.0317.54% (+0.18)
Jul 31, 20252025 (Q2)0.921.080.33230.56% (+0.75)
May 08, 20252025 (Q1)0.850.880.081014.94% (+0.80)
Feb 06, 20252024 (Q4)0.830.860.12598.53% (+0.74)
Nov 04, 20242024 (Q3)0.801.030.29255.14% (+0.74)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed